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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Surgery is one of the treatment choices for Graves disease. The residual
thyroid tissue may shrink or become larger. The object of this study was trying to find out what
factors affect the residual thyroid gland volume change after thyroidectomy in Graves disease.
Methods: We followed thyroid volume changes by ultrasonography in 101 patients with Graves
disease who underwent one side lobectomy and another side subtotal thyroidectomy from
1996 to 2006. These patients were divided into three groups according to the residual thyroid
size increasing, no change in size, and shrinking. We checked the factors as follows: age, body
weight, thyroid-stimulating hormone (TSH) level, TSH-receptor antibody level, anti-thyroid
peroxidase (TPO) antibody level, total thyroid volume before and after thyroidectomy, and
degree of lymphocyte infiltration.
Results: We found that young age and lower residual volume ratio were the most powerful two
factors affecting remnant thyroid gland volume changing. We also found that there is no signif-
icant correlation between TSH levels and thyroid volume change, nor TSH-receptor antibody
titer or thyroid volume change.
Conclusion: Age and residual volume ratio were the most powerful two factors in this study.
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630 P.-Y. Chen et al.Introduction the final examination volume. The year-volume change rateThe prevalence of hyperthyroidism is approximately 1%e2%
in women and 0.1% in men.1 Treatments for Graves disease
include antithyroid drugs, radioactive iodine ablation, and
surgery. It is unclear which of these therapies is optimal.
For patients with intractable hyperthyroidism or large
goiters, surgery is the favored means of treatment.1
In clinical practice, residual thyroid gland volume may
variously change. Ultrasonography is a useful tool for
thyroid examination and is widely used to assess thyroid
gland size.2,3 To date, however, there have been no reports
published describing serial residual thyroid changes as
determined by neck ultrasound following thyroidectomy.
Thyroid-stimulating hormone (TSH)-receptor antibody
(TSHRAb) and TSH are potent goitrogenic factors.4e6 Phys-
iologically, TSH affects thyrocyte function and can promote
cellular hypertrophy. The majority of TSHRAbs have TSH-
like effects, while TSHRAbs exert stimulatory, neutral-
izing, and antagonistic effects. Few investigations have
focused on the hyperplastic thyroid cell in studies per-
taining to the involvement of growth factors in the devel-
opment of thyroid cancer. The aim of this study was to
determine if any clinical, biochemical, or histological
factors are related to changes in residual thyroid volume in
patients with Graves disease after thyroidectomy.Figure 1 Relationship between the rate of volume change
and patient age. There was a negative correlation between the
rate of volume change and patient age (r Z e0.230,
p Z 0.030).Materials and methods
A total of 101 patients with Graves disease who underwent
one side lobectomy and another side subtotal thyroidec-
tomy were studied from 1996 to 2006. There were 88
women and 13 men with a mean overall age of 39  12.4
years (range: 18e73 years). The TSH, TSHRAb, and anti-
thyroid peroxidase antibody (ATPO) levels were all
measured postoperatively. We measured TSHRAb concen-
trations by radioreceptor assay using the porcine TSH
receptor by electrochemiluminescence immunoassay
(ECLIA) with the Roche Elecsys 2010 assay (Roche Diag-
nostic Systems, Mannheim, Germany). We reviewed the
surgical specimens and assessed the degree of lymphocyte
infiltration subjectively with a classification of slight,
moderate, and severe. The volume of residual thyroid
tissue was determined by ultrasonography every 3 to 6
months for 1 to 10 years. The mean follow-up duration was
2.5 years, and the mean number of thyroid ultrasonography
performed was 11.2 times. All thyroid remnants weighed
less <3 g after thyroidectomy. Fifty percent patients had
subclinical hypothyroidism during follow-up, and ten
percent developed clinical hypothyroidism. There was no
patient have recurrent thyrotoxicosis. During the follow-up
period, no patients received antithyroid medication or
thyroxin supplement. For those 10% of patients who later
developed clinical hypothyroidism, we started eltroxin
supplement and stopped collecting their TSH level and
other laboratory data.
All measurements were made by the same operator to
reduce interobserver error (intraobserver error was <2.5%).
The rate of volume change was defined as follows: Vn-V1/
V1, where V1 is the initial examination volume, and Vn iswas defined as the volume change rate over time.
Other variables assessed included age at the time of
surgery, body weight, surface area, TSHRAb level
(expressed as times of upper normal limit), TSH level
(expressed as the log value), anti-TPO antibody (ATPO),
duration of follow-up, total thyroid volume before
thyroidectomy, residual volume ratio (residual volume/
total volume), and degree of lymphocyte infiltration.7
Thyroid volume was calculated as follows:
(length  width  height)/2. A volume change rate of less
than 7% was defined as no volume change in this study. This
study was reviewed and approved by the Institutional
Review Board committee and informed consent was ob-
tained from all patients.
Statistical analysis
Data are reported as mean  standard deviation. Analysis
was performed with the statistical package SPSS 17.0 (IBM
Software). Differences between parameters were
compared with the Chi-square test (Cramer V), two-way
analysis of variance (ANOVA). Relationships among param-
eters were tested by the Pearson correlation coefficient.
Study parameters that had non-Gaussian distributions were
transformed to log values. Results were considered statis-
tically significant at p < 0.05.
Results
There were significant inverse correlations between the
rate of volume increase and patient age (r Z e0.230,
p Z 0.030; Fig. 1) and residual volume ratio (r Z e0.249,
p Z 0.015; Fig. 2). There was no significant relationship
Figure 2 Relationship between the rate of volume change
and residual volume ratio. There was a negative correlation
between the rate of volume change and residual volume ratio
(r Z e0.249, p Z 0.015).
Size change post-thyroidectomy in Graves 631between volume change rate or year volume change and
the other variables assessed.
Of the 101 patients, 16 (15.7%) had no change in thyroid
volume (Group A: rate of volume change 7% and e7%),
59 patients (57.8%) had increased thyroid volume (Group B:
rate of volume change >7%), while 26 patients (25.5%) had
decreased thyroid volume (Group C: rate of volume change
<e7%). There were significantly more TSHRAb-negative
patients in Group C compared with both other groups
(31% in Group A vs. 24% in Group B vs. 46% in Group C;
p Z 0.048; Fig. 3). There were no between group differ-
ences in the ATPO-positive rate (76% in Group A vs. 82% in
Group B vs. 80% in Group C).
The rate of volume change was not related with mean
TSHRAb in Group B patients (r Z 0.025, p Z 0.057). But
there was a tendency for the rate of volume change inFigure 3 Percentage of TSHRAb in each group. Group C had
more TSHRAb negative patients (pZ 0.048) than other groups.
Light color: TSHRAb negative; deep color: TSHRAb positive.
TSHRAb Z thyroid-stimulating hormone-receptor antibody.TSHRAb-positive Group C patients to be inversely related
with TSHRAb titer (p Z 0.09) (Fig. 4).
Discussion
There are many known factors associated with thyroid
gland size, such as iodine status, TSH level, TSHRAb,
smoking, lithium treatment, and cytokines. In this study,
we focus on clinical factors including age, thyroid function
status, serum TSH and autoantibodies levels, pre- and
postoperative thyroid volume, and lymphocyte infiltration.
We found that there was a negative correlation between
the rate of residual thyroid volume increase and patient
age. This finding suggests that the size of remnant thyroid
tissue is more likely to increase in patients who are younger
at the time of surgery. In a previous study, Orgiazzi et al8e11
found that young age was one of the major variables
related to the subsequent risk of relapse after withdrawal
of medical therapy in patients with Graves disease. Does
this imply the juvenile Graves disease is more aggressive?
Maiorano and colleagues12 findings suggest that insulin-like
growth factor 1 (IGF-1) and the IGF-1 receptor may be
actively involved in the pathogenesis of Graves disease. The
known decrease in IGF-1 levels with age may explain the
link between young age and thyroid proliferation.
Although both TSHRAb and TSH levels are known to be
potent goitrogenic factors,4e6 we found no significant
correlation between TSH levels and thyroid volume change
in any group of patients. Similarly, TSHRAb titer was not
correlated with the rate of volume increase.
In the present study it was found that there were more
TSHRAb -negative patients amongst those who exhibited
a decrease in residual thyroid volume. Bojarska-Szmygin3,13
reported that TSHRAb level was correlated with thyroidFigure 4 Relationship between the rate of volume change
and mean TSHRAb titer. The rate of volume change was not
correlated with mean TSHRAb titer in group B patients
(rZ 0.025, pZ 0.057). Mean TSHRAb titer: the mean value of
TSHRAb titers in each patient. TSHRAb Z thyroid-stimulating
hormone-receptor antibody.
632 P.-Y. Chen et al.size. Hence, low TSHRAb levels presumably contribute to
thyroid tissue shrinkage. In these patients, there was
a tendency for the decrease in volume to be inversely
related with the TSHRAb titer. An increase in the proportion
of TSHR blocking antibody may underlie this finding. It has
previously been found that anti-TPOAb levels are related
with Hashimoto destructive action. No such relationship
was found in the present study. Similar to the result of the
study from Rieu et al,3 the TPOAb may play less of a role in
modifying remnant thyroid volume change in patients with
Graves disease.
The lymphocyte infiltration was hypothetically related
to postoperative hypothyroidism. In Olsen et al,14 they
found the there was some correlation between the degree
of lymphocyte infiltration and the development of post-
operative hypothyroidism, but it did not indicate a mark-
edly increased tendency to hypothyroidism. But in
Hargreaves et al,15 surgical treated thyrotoxicosis showed
postoperative hypothyroidism occurred exclusively in those
moderate or severe focal lymphocyte infiltration. When it
comes to postoperative thyroid volume change, our result
showed there was no change.
In 1995, Takai16 performed a study to evaluate clinical
factors in subtotal thyroidectomy in Graves disease. He
found that postoperative thyroid volume and weight were
larger in patients with relapse than in patients in remission
and in hypothyroid status. He also found a significant corre-
lation between serum thyroglobulin level and the post-
operative thyroid volume, and also thyroglobulin level in
patientswith relapsewas significantly higher thanothers.We
know that larger remnant thyroid weight is related to higher
risk for relapse, and thyroglobulin level may reflect the
thyroid volume. In our study, we did not check thyroglobulin
level routinely, thus we did not find these clues.
Cytokines are known to related to thyroid cell prolifer-
ation. In Matsunaga et al,17 interferon-gamma induces
human leukocyte antigen (HLA)-DR antigen expression on
thyrocytes from patients with Graves disease, and these
cells induce proliferation of autologous T cells, which may,
in turn, act on thyrocytes to perpetuate the process. Genes
have been shown to contribute to the etiology of Graves
disease, and the substitution of the amino acid Ala or Gln
with arginine at position beta 74 in the HLA-DR peptide
binding pocket is the recently found specific sequence
change causing Graves disease.18 However, among to Asian
people, prevalence and many clinical presentations are
much different from Caucasians. The recently study even
identified distinct Graves disease-associated alleles.19 If
available, further investigation in genes may answer more
details about thyroid volume changing in Graves disease.
Although we did not find any correlation between preop-
erative thyroid size and remnant thyroid volume change,
a negative correlation between the rate of thyroid volume
increase and the residual volume ratio was found. This
implies that thyroid proliferation may be induced post-
operatively in patients with larger preoperative goiters.
Excessive thyroid tissue removal may induce transient
hypothyroidism and provoke TSH release, but we found no
significant correlation between TSH levels and thyroid
volume change. Furthermore, there were no instances of
recurrent hyperthyroidism in this series (30% of patients
received thyroxin supplement postoperatively after thisstudy). The small amount of remnant thyroid (mostly
2.0e2.5 g) may explain the lack of recurrence. The rela-
tionship between thyroid function and thyroid volume
change warrants further investigation in a cohort study of
longer duration.
There are limitations in our study. First, we know there
are two types of TSHRAbswith distinct functions. Stimulating
antibodies promote thyroid growth and secretion, while
blocking antibodies show inhibitory function. In our study,we
used ECLIA method to measure TSHRAb concentrations, but
we cannot distinguish these TSHRAb functions. Second, we
used ultrasonography to measure thyroid gland size.
Although all the measurements were made by the same
operator to reduce interobserver error, the ultrasonography
can not completely represent real thyroid remnant sizes. We
look forward to new studies that can provide more informa-
tion about thyroid remnant volume change.
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